Södertälje, Sweden

Panagiotis Ioannidis


Average Co-Inventor Count = 5.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Spånga, SE (2003)
  • Södertälje, SE (2006)

Company Filing History:


Years Active: 2003-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Panagiotis Ioannidis: Innovator in Pharmaceutical Chemistry

Introduction

Panagiotis Ioannidis is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the preparation of enantiomerically enriched compounds. With a total of two patents to his name, his work has implications for treating insulin resistance syndrome.

Latest Patents

One of his latest patents is focused on a process for the preparation of enantiomerically enriched compounds. This invention relates to novel resolution methods that are useful in the preparation of enantiomerically enriched intermediates. These intermediates are essential for developing compounds that have a pharmacological effect on insulin resistance syndrome. Specifically, the patent defines a process for preparing the (S)-enantiomer of certain 2-ethoxy-3-(4-hydroxyphenyl)propanoic acids and their derivatives.

Career Highlights

Panagiotis Ioannidis is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on innovative solutions in drug development. His expertise in pharmaceutical chemistry has positioned him as a valuable asset in the industry.

Collaborations

Throughout his career, Panagiotis has collaborated with esteemed colleagues, including Kjell Andersson and Alan Eric Fischer. These collaborations have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Panagiotis Ioannidis is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of insulin resistance syndrome. His innovative patents and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…